New drug cocktail shows promise against rare blood cancer in young patients
NCT ID NCT03710772
First seen Nov 06, 2025 · Last updated May 06, 2026 · Updated 28 times
Summary
This study tests a mix of targeted drugs (ibrutinib, rituximab, venetoclax) plus chemotherapy in 51 young adults newly diagnosed with mantle cell lymphoma, a rare blood cancer. The goal is to see how well the combination shrinks tumors and controls the disease. Participants receive the treatment in phases, and researchers monitor side effects closely.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.